ESPR vs. LYEL, RVNC, NKTX, IGMS, LXRX, ANRO, MRNS, PAHC, MRSN, and OCS
Should you be buying Esperion Therapeutics stock or one of its competitors? The main competitors of Esperion Therapeutics include Lyell Immunopharma (LYEL), Revance Therapeutics (RVNC), Nkarta (NKTX), IGM Biosciences (IGMS), Lexicon Pharmaceuticals (LXRX), Alto Neuroscience (ANRO), Marinus Pharmaceuticals (MRNS), Phibro Animal Health (PAHC), Mersana Therapeutics (MRSN), and Oculis (OCS). These companies are all part of the "pharmaceutical preparations" industry.
Lyell Immunopharma (NASDAQ:LYEL) and Esperion Therapeutics (NASDAQ:ESPR) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, community ranking, risk, media sentiment, analyst recommendations, earnings, valuation, dividends and institutional ownership.
66.1% of Lyell Immunopharma shares are owned by institutional investors. Comparatively, 47.4% of Esperion Therapeutics shares are owned by institutional investors. 24.0% of Lyell Immunopharma shares are owned by insiders. Comparatively, 0.6% of Esperion Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Esperion Therapeutics has a net margin of -179.87% compared to Esperion Therapeutics' net margin of -180,486.14%. Lyell Immunopharma's return on equity of 0.00% beat Esperion Therapeutics' return on equity.
Lyell Immunopharma presently has a consensus price target of $5.50, suggesting a potential upside of 146.64%. Esperion Therapeutics has a consensus price target of $9.33, suggesting a potential upside of 248.26%. Given Lyell Immunopharma's higher possible upside, analysts plainly believe Esperion Therapeutics is more favorable than Lyell Immunopharma.
Lyell Immunopharma has a beta of -0.5, meaning that its stock price is 150% less volatile than the S&P 500. Comparatively, Esperion Therapeutics has a beta of 0.82, meaning that its stock price is 18% less volatile than the S&P 500.
Esperion Therapeutics received 584 more outperform votes than Lyell Immunopharma when rated by MarketBeat users. Likewise, 69.71% of users gave Esperion Therapeutics an outperform vote while only 54.55% of users gave Lyell Immunopharma an outperform vote.
Esperion Therapeutics has higher revenue and earnings than Lyell Immunopharma. Lyell Immunopharma is trading at a lower price-to-earnings ratio than Esperion Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Esperion Therapeutics had 28 more articles in the media than Lyell Immunopharma. MarketBeat recorded 31 mentions for Esperion Therapeutics and 3 mentions for Lyell Immunopharma. Esperion Therapeutics' average media sentiment score of 0.82 beat Lyell Immunopharma's score of 0.30 indicating that Lyell Immunopharma is being referred to more favorably in the media.
Summary
Esperion Therapeutics beats Lyell Immunopharma on 11 of the 18 factors compared between the two stocks.
Get Esperion Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ESPR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ESPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Esperion Therapeutics Competitors List
Related Companies and Tools